Treatment of BRAF V600E mutant gastrointestinal stromal tumor with dabrafenib: a case report

Abstract excerpt

Background: Gastrointestinal stromal tumor (GIST) is a rare mesenchymal tumor arising in the gut, most commonly stomach or small bowel. The most common driver mutations are KIT and PDGFRA which can be treated with imatinib or avapritinib (for PDGFRA D842V-mutant GIST), respectively. BRAF V600E mutant GISTs are rare and these do not respond to imatinib. Multiple clinical trials have shown antitumor effects with...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Gastric Cancer Management and Outcomes
• Share to Gastrointestinal Tumor Research and Treatment
• Share to Neurofibromatosis and Schwannoma Cases